Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice. 2016

Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
Department of Pharmacology and Toxicology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran. ; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Creatine exerts beneficial effects on a variety of pathologies in which energy metabolism and oxidative stress play an etiological role. Creatine supplements have shown beneficial effects on neurological disorders including Parkinson׳s disease, Huntington›s disease, amyotrophic lateral sclerosis, as well as Alzheimer›s disease and stroke. However, the potential benefits of creatine for patients with convulsive disorders remain poorly defined. While some authors did not suggest any anti- or pro-convulsant roles for creatine treatment, others suggest that creatine may be an anticonvulsant agent. In this study, we investigated the effects of creatine on seizures in mice. Three models were used to explore the role of creatine on seizures in mice including intravenous pentylenetetrazole (PTZ), intraperitoneal PTZ, and electroshock models. Acute creatine treatment (10, 20, 40 and 80 mg/Kg) significantly increased the clonic seizure threshold in the intravenous PTZ model. Sub-chronic administration of creatine (10 and 20 mg/Kg) revealed a significant anticonvulsant effect in intravenous PTZ model. Acute creatine administration (10, 20 and 40 mg/Kg) significantly decreased the frequency of clonic seizures in the intraperitoneal PTZ model. Besides, acute creatine (40 and 80 mg/Kg) decreased the incidence of tonic seizures after electroshock. In conclusion, creatine exerts anticonvulsant effects in three seizure models; therefore, it may act as a potential drug to help patients with convulsions. However, further investigations should be done to clarify these results more.

UI MeSH Term Description Entries

Related Publications

Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
December 2003, Annals of the New York Academy of Sciences,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
October 2018, International journal of molecular sciences,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
September 2005, Brain research bulletin,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
October 1996, Neuroscience letters,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
January 1986, Annals of the New York Academy of Sciences,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
January 1981, Proceedings of the Western Pharmacology Society,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
January 1991, Peptides,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
February 1989, Prostaglandins, leukotrienes, and essential fatty acids,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
October 2003, Indian journal of physiology and pharmacology,
Hamed Shafaroodi, and Farnaz Shahbek, and Mehrdad Faizi, and Farzad Ebrahimi, and Leila Moezi
August 2023, Heliyon,
Copied contents to your clipboard!